Literature DB >> 9037645

A cost analysis of a treatment policy of a deliberate perioperative increase in oxygen delivery in high risk surgical patients.

J F Guest1, O Boyd, W M Hart, R M Grounds, E D Bennett.   

Abstract

OBJECTIVE: To investigate the cost implications of a treatment policy of a deliberate perioperative increase of oxygen delivery in high risk surgical patients.
DESIGN: A cost-effectiveness analysis comparing 'protocol' high risk surgical patients in whom oxygen delivery was specifically targeted towards 600 ml/min/m2 with 'control' patients.
INTERVENTIONS: In a randomised, controlled clinical trial we previously demonstrated a significant reduction in mortality (5.7% vs 22.2%, p = 0.015) and morbidity (0.68 +/- 0.16 complications vs 1.35 +/- 0.20, p = 0.008) in 'protocol' high risk surgical patients in whom oxygen delivery was specifically targeted towards 600 ml/min per m2 compared with 'control' patients. This current study retrospectively analysed the medical care and National Health Service resource use of each patient in the trial. Departmental purchasing records and business managers were consulted to identify the unit cost of these resources, and thereby the cost of treating each patient was calculated.
RESULTS: The median cost of treating a protocol patient was lower than for a control patient (6,525 pounds vs 7,784 pounds) and this reduction was due mainly to a decrease in the cost of treating postoperative complications (median 213 pounds vs 668 pounds). The cost of obtaining a survivor was 31% lower in the protocol group.
CONCLUSION: Perioperative increase of oxygen delivery in high risk surgical patients not only improves survival, but also provides an actual and relative cost saving. This may have important implications for the management of these patients and the funding of intensive care.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9037645     DOI: 10.1007/s001340050295

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  10 in total

1.  Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK.

Authors:  T N Flynn; S M Kelsey; D L Hazel; J F Guest
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

2.  Goal-directed intraoperative fluid therapy guided by stroke volume and its variation in high-risk surgical patients: a prospective randomized multicentre study.

Authors:  Thomas W L Scheeren; Christoph Wiesenack; Herwig Gerlach; Gernot Marx
Journal:  J Clin Monit Comput       Date:  2013-04-05       Impact factor: 2.502

3.  Early goal-directed therapy after major surgery reduces complications and duration of hospital stay. A randomised, controlled trial [ISRCTN38797445].

Authors:  Rupert Pearse; Deborah Dawson; Jayne Fawcett; Andrew Rhodes; R Michael Grounds; E David Bennett
Journal:  Crit Care       Date:  2005-11-08       Impact factor: 9.097

Review 4.  Year in review 2005: critical care--cardiology.

Authors:  Timothy Gatheral; E David Bennett
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

Review 5.  Clinical review: how to optimize management of high-risk surgical patients.

Authors:  Rupert M Pearse; Andrew Rhodes; R Michael Grounds
Journal:  Crit Care       Date:  2004-08-06       Impact factor: 9.097

6.  Clinical review: Goal-directed therapy-what is the evidence in surgical patients? The effect on different risk groups.

Authors:  Maurizio Cecconi; Carlos Corredor; Nishkantha Arulkumaran; Gihan Abuella; Jonathan Ball; R Michael Grounds; Mark Hamilton; Andrew Rhodes
Journal:  Crit Care       Date:  2013-03-05       Impact factor: 9.097

7.  Cost-effectiveness of a cardiac output-guided haemodynamic therapy algorithm in high-risk patients undergoing major gastrointestinal surgery.

Authors:  Zia Sadique; David A Harrison; Richard Grieve; Kathryn M Rowan; Rupert M Pearse
Journal:  Perioper Med (Lond)       Date:  2015-12-14

8.  Cost analysis of the stroke volume variation guided perioperative hemodynamic optimization - an economic evaluation of the SVVOPT trial results.

Authors:  Jan Benes; Jan Zatloukal; Alena Simanova; Ivan Chytra; Eduard Kasal
Journal:  BMC Anesthesiol       Date:  2014-05-22       Impact factor: 2.217

9.  Tackling the economic burden of postsurgical complications: would perioperative goal-directed fluid therapy help?

Authors:  Gerard R Manecke; Angela Asemota; Frederic Michard
Journal:  Crit Care       Date:  2014-10-11       Impact factor: 9.097

10.  Impact of perioperative hemodynamic optimization therapies in surgical patients: economic study and meta-analysis.

Authors:  João M Silva-Jr; Pedro Ferro L Menezes; Suzana M Lobo; Flávia Helena S de Carvalho; Mariana Augusta N de Oliveira; Francisco Nilson F Cardoso Filho; Bruna N Fernando; Maria Jose C Carmona; Vanessa D Teich; Luiz Marcelo S Malbouisson
Journal:  BMC Anesthesiol       Date:  2020-03-31       Impact factor: 2.217

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.